An evaluation of alirocumab for the treatment of hypercholesterolemia

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 12, 2015, Pages 1307-1323

  Farnier, Michel ^a  

^a Lipid Clinic   (France)

Author keywords

Alirocumab; Cardiovascular disease; Hypercholesterolemia; LDL cholesterol; PCSK9

Indexed keywords

ALIROCUMAB; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; MORBIDITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG EFFECTS; LIPID METABOLISM; METABOLISM;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84948570297     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1111759     Document Type: Article

References (81)

1. Baigent C, Keech A, Kearney P, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278.
2. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681.
3. Reiner Z, Catapano AL, De Backer G, et al. ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2011; 32: 1769-1818.
4. Peck J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012; 33: 1635-1701.
5. Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerosis cardiovascular risk in adults. Circulation. 2014; 129 (25 Suppl 2): S1-S45.
6. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events. A meta-analysis of statin trials. J Am Coll Cardiol. 2014; 64: 485-494.
7. Robinson JG, Stone NJ. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J. 2015;36:2110-2118.
8. Kataoka Y, St John J, Wolski K, et al. Atheroma progression in hyporesponders to statin therapy. Arterioscler Thromb Vasc Biol. 2015; 35: 990-995.
9. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372: 2387-2397.
10. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012; 60: 2631-2639.
11. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2x2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015; 65: 1552-1561.
12. Catapano AL, Ference BA. IMPROVE-IT and genetics reaffirm the causal role of LDL in cardiovascular disease. Atherosclerosis. 2015; 241: 498-501.
13. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015; 36: 1012-1022.
14. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34: 154-156.
15. Cohen J, Pertsemlidis A, Korowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005; 37: 161-165.
16. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354: 1264-1272.
17. Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010; 55: 2833-2842.
18. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012; 11: 367-383.
19. Seidah NG, Awan Z, Chrétien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014; 114: 1022-1036.
20. Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res. 2012; 53: 2515-2524.
21. Norata GD, Tibolla G, Catapano AL. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Vascul Pharmacol. 2014; 62: 103-111.
22. Urban D, Pöss J, Böhm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013; 62: 1401-1408.
23. Farnier M. PCSK9: from discovery to therapeutic applications. Arch Cardiovasc Dis. 2014; 107: 58-66.
24. Marais AD, Kim JB, Wasserman SM, et al. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacol Ther. 2015; 145: 58-66.
25. Cui C-J, Li S, Li J-J. PCSK9 and its modulation. Clin Chim Acta. 2015; 440: 79-86.
26. Hedrick JA. Targeting PCSK9 for the treatment of hypercholesterolemia. Curr Opin Invest Drugs. 2009; 10: 938-946.
27. Rhainds D, Arsenault BJ, Tardif J-C. PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials. Clin Lipid. 2012; 7: 621-640.
28. Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets. 2009; 13: 19-28.
29. Hooper AJ, Burnett JR. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2013; 13: 429-435.
30. Farnier M. PCSK9 inhibitors. Curr Opin Lipidol. 2013; 24: 251-258.
31. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014; 11: 563-575.
32. Praluent (alirocumab) injection. FDA document-BLA 125559. FDA Center for Drug Evaluation and Research. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting; 2015. Jun 9; [cited 2015 Aug 10]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM449865.pdf.
33. Praluent prescribing information. [cited 2015 Aug 10]. Available from: www.regeneron.com/Praluent/Praluent-fpi.pdf.
34. Roth EM, Diller P. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiol. 2014; 10: 183-199.
35. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012; 366: 1108-1118.
36. Lunven C, Paehler T, Poitiers F, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014; 32: 297-301.
37. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969; 13: 1-110.
38. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012; 59: 2344-2353.
39. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REG727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012; 380: 29-36.
40. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012; 367: 1891-1900.
41. Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of Alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014; 114: 711-715.
42. Robinson JG, Farnier M, Krempf M, et al. for the ODYSSEY LONG TERM investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1489-1499.
43. Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78-week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia. Eur Heart J. 2015 Sept 1. pii:ehv370. [Epub ahead of print]
44. Ginsberg HN, Rader D, Raal FJ. et al. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe familial hypercholesterolemia. Presented at the American Heart Association Scientific Sessions; 2014 Nov 17; Chicago, IL.
45. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015; 169: 906-915.
46. Stroes E, Guyton J, Farnier M, et al. Efficacy and safety of alirocumab 150 mg and 300 mg every four weeks in patients with uncontrolled hypercholesterolemia: the ODYSSEY CHOICE I and CHOICE II studies. Presented at the American College of Cardiology Sessions; 2015 Mar 17; San Diego CA; abstract 1107-105.
47. Stroes E, Guyton JR, Farnier M, et al. for the ODYSSEY CHOICE II investigators. Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. Presented at the ISA meeting at the late breaker session; 2015 Jun; Amsterdam, NL.
48. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015; 36: 1186-1194.
49. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin- re-challenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015. DOI: 10.1016/j.jacl.2015.08.006.
50. Roth EM, Taskinen M-R, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014; 176: 55-61.
51. Bays H, Gaudet D, Weiss R, et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J Clin Endocrinol Metab. 2015; 100: 3140-3148.
52. Farnier M, Jones P, Severance R, et al. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis. Forthcoming 2015.
53. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014; 168: 682-689.
54. Sabatine MS, Giugliano RP, Wiviott SD, et al. for the open-label study of long-term evaluation against LDL-cholesterol (OSLER) investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1500-1509.
55. Kastelein JJP, Robinson JG, Farnier M, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014; 28: 281-289.
56. Kastelein JJP, Farnier M, Hovingh GK, et al. Efficacy and safety of the PCSK9 monoclonal antibody alirocumab vs placebo in 1254 patients with heterozygous familial hypercholesterolemia (HeFH): analyses up to 78 weeks from four ODYSSEY trials. Presented at European Society of Cardiology Sessions; 2014 Sept; London, UK; abstract.
57. Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ Cardiovasc Genet. 2015 Sept 15. pii:CIRCGENETICS.115.001129. [Epub ahead of print]
58. Lambert G, Chatelais M, Petrides F, et al. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab. J Am Coll Cardiol. 2014; 64: 2299-2300.
59. Raal FJ, Honarpour N, Blom DK, et al. for the TESLA investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 385: 341-350.
60. Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trials. J Clin Lipidol. 2014; 8: 554-561.
61. Robinson JG, Colhoun HM, Bays HE, et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS studies. Clin Cardiol. 2014; 37: 597-604.
62. Kühnast S, van der Hoorn JWA, Pieterman EJ, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014; 55: 2103-2112.
63. Robinson J, Farnier M, Chaudhari U, et al. Adverse events in patients with low-density lipoprotein cholesterol levels < 25 or < 15 mg/dL on at least two consecutive visits in fourteen randomized, controlled, clinical trials of alirocumab. Presented at American College of Cardiology Sessions; 2015 Mar 17; San Diego, CA; abstract 1164M-05.
64. Ridker PM. Lipids and cardiovascular disease 1. LDL-cholesterol: controversies and future therapeutic directions. Lancet. 2014; 384: 607-617.
65. Gitt AK, Drexel H, Feely J, et al. on behalf of the DYSIS investigators. Persistent lipid abnormalies in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol. 2012; 19: 221-230.
66. Gencer B, Auer R, Nanchen D, et al. Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis. 2015; 239: 118-124.
67. Romagnuolo R, Scipione CA, Boffa MB, et al. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem. 2015; 290: 11649-11662.
68. Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 2011; 31: 785-791.
69. Rashid S, Tavori H, Brown PE, et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglycerides-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation. 2014; 130: 431-441.
70. Levy E, Ouadda ABD, Spahis S, et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis. 2013; 227: 297-306.
71. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013; 228: 18-28.
72. Sattar NA, Ginsberg H, Ray K, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atherosclerosis Suppl. 2014; 15: 1-15.
73. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2010; 584: 701-706.
74. Bonnefond A, Yengo L, Le May C, et al. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis. Diabetologia. 2015; 58: 2051-2055.
75. Cariou B, Benoit I, Le May C. Preserved adrenal function in fully PCSK9-deficient subject. Int J Cardiol. 2014; 176: 499-500.
76. Labonte P, Begley S, Guevin C, et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology. 2009; 50: 17-24.
77. Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver generation. Hepatology. 2008; 48: 646-654.
78. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J. 2013; 34: 3478-3490.
79. Besseling J, Kindt I, Hof M, et al. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis. 2014; 233: 219-223.
80. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010; 209: 184-194.
81. Mundal L, Sarancic M, Ose L, et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. J Am Heart Assoc. 2014; 3: e001236. DOI:10.1161/JAHA.114.001236